Common gene rearrangements in prostate cancer

Journal of Clinical Oncology

Volumn 29, Issue 27, 2011, Pages 3659-3668

  Rubin, Mark A ^a   Maher, Christopher A ^b   Chinnaiyan, Arul M ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; B RAF KINASE; CETUXIMAB; ESRP1 PROTEIN; MYC PROTEIN; NDRG1 PROTEIN; NKX3.1 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN KINASE B; RAF1 PROTEIN; SLC45A3 PROTEIN; SORAFENIB; TMPRSS2 PROTEIN; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETV4; UNCLASSIFIED DRUG;

ADVANCED CANCER; APOPTOSIS; CANCER DIAGNOSIS; CANCER SURVIVAL; GENE FUSION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; REVIEW;

GENE REARRANGEMENT; HUMANS; MALE; ONCOGENE FUSION; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS;

EID: 80053078529     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.1916     Document Type: Review

References (78)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
2. Tomlins SA, Rhodes DR, Perner S, et al: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648, 2005 (Pubitemid 41528150)
3. Rubin MA, Chinnaiyan AM: Bioinformatics approach leads to the discovery of the TMPRSS2: ETS gene fusion in prostate cancer. Lab Invest 86:1099-1102, 2006 (Pubitemid 44624146)
4. Hanauer DA, Rhodes DR, Sinha-Kumar C, et al: Bioinformatics approaches in the study of cancer. Curr Mol Med 7:133-141, 2007 (Pubitemid 46322284)
5. Tomlins SA, Mehra R, Rhodes DR, et al: TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66:3396-3400, 2006
6. Nelson WG, De Marzo AM, Isaacs WB: Prostate cancer. N Engl J Med 349:366-381, 2003 (Pubitemid 36886244)
7. Lapointe J, Li C, Higgins JP, et al: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 101:811-816, 2004 (Pubitemid 38121040)
8. Lapointe J, Kim YH, Miller MA, et al: A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 20:467-473, 2007 (Pubitemid 46482370)
9. Maher CA, Kumar-Sinha C, Cao X, et al: Transcriptome sequencing to detect gene fusions in cancer. Nature 458:97-101, 2009
10. Rickman DS, Pflueger D, Moss B, et al: SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res 69:2734-2738, 2009
11. Esgueva R, Perner S, J LaFargue C, et al: Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol 23:539-546, 2010
12. Han B, Mehra R, Dhanasekaran SM, et al: A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: Identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 68:7629-7637, 2008
13. Maher CA, Palanisamy N, Brenner JC, et al: Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A 106:12353-12358, 2009
14. Pflueger D, Rickman DS, Sboner A, et al: N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 11:804-811, 2009
15. Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al: Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16:793-798, 2010
16. Tomlins SA, Rhodes DR, Yu J, et al: The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 13:519-528, 2008 (Pubitemid 351763901)
17. Perner S, Demichelis F, Beroukhim R, et al: TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66:8337-8341, 2006 (Pubitemid 44449140)
18. Mosquera JM, Perner S, Genega EM, et al: Characterization of TMPRSS2-ERG fusion highgrade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 14:3380-3385, 2008
19. Perner S, Mosquera JM, Demichelis F, et al: TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol 31:882-888, 2007 (Pubitemid 47165141)
20. De Marzo AM, Platz EA, Epstein JI, et al: A working group classification of focal prostate atrophy lesions. Am J Surg Pathol 30:1281-1291, 2006 (Pubitemid 44454708)
21. Cerveira N, Ribeiro FR, Peixoto A, et al: TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8:826-832, 2006 (Pubitemid 44564838)
22. Park K, Tomlins SA, Mudaliar KM, et al: Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12:590-598, 2010
23. Ahlers CM, Figg WD: ETS-TMPRSS2 fusion gene products in prostate cancer. Cancer Biol Ther 5:254-255, 2006
24. Clark J, Merson S, Jhavar S, et al: Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 26:2667-2673, 2007 (Pubitemid 46632014)
25. Hermans KG, Van Marion R, Van Dekken H, et al: TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 66:10658-10663, 2006 (Pubitemid 44876959)
26. Iljin K, Wolf M, Edgren H, et al: TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66:10242-10246, 2006 (Pubitemid 44799738)
27. Liu W, Chang B, Sauvageot J, et al: Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Genes Chromosomes Cancer 45:1018-1032, 2006 (Pubitemid 44435536)
28. Soller MJ, Isaksson M, Elfving P, et al: Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45:717-719, 2006 (Pubitemid 43727158)
29. Wang J, Cai Y, Ren C, et al: Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66:8347-8351, 2006 (Pubitemid 44449142)
30. Attard G, Clark J, Ambroisine L, et al: Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27:253-263, 2008
31. Nam RK, Sugar L, Wang Z, et al: Expression of TMPRSS2 ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 6:40-45, 2007 (Pubitemid 46294173)
32. Rajput AB, Miller MA, De Luca A, et al: Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 60:1238-1243, 2007 (Pubitemid 350084545)
33. Winnes M, Lissbrant E, Damber JE, et al: Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 17:1033-1036, 2007
34. Yoshimoto M, Ludkovski O, Bayani J, et al: Microdeletion and concurrent translocation associated with a complex TMPRSS2:ERG prostate cancer gene fusion. Genes Chromosomes Cancer 46:861-863, 2007 (Pubitemid 47106190)
35. Saramäki OR, Harjula AE, Martikainen PM, et al: TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 14:3395-3400, 2008
36. Mehra R, Tomlins SA, Shen R, et al: Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20:538-544, 2007 (Pubitemid 46631996)
37. Tomlins SA, Laxman B, Dhanasekaran SM, et al: Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448:595-599, 2007 (Pubitemid 47206938)
38. Helgeson BE, Tomlins SA, Shah N, et al: Characterization of TMPRSS2:ETV5 and SLC45A3: ETV5 gene fusions in prostate cancer. Cancer Res 68:73-80, 2008 (Pubitemid 351380107)
39. Yoshimoto M, Joshua AM, Chilton-Macneill S, et al: Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 8:465-469, 2006 (Pubitemid 44035330)
40. Tu JJ, Rohan S, Kao J, et al: Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: Frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 20:921-928, 2007 (Pubitemid 47267823)
41. Setlur SR, Mertz KD, Hoshida Y, et al: Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100:815-825, 2008 (Pubitemid 351809667)
42. Demichelis F, Fall K, Perner S, et al: TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26:4596-4599, 2007 (Pubitemid 47037039)
43. Mehra R, Tomlins SA, Yu J, et al: Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68:3584-3590, 2008
44. Mosquera JM, Mehra R, Regan MM, et al: Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 15:4706-4711, 2009
45. Marcucci G, Baldus CD, Ruppert AS, et al: Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study. J Clin Oncol 23:9234-9242, 2005
46. Porter CR, Kodama K, Gibbons RP, et al: 25-year prostate cancer control and survival outcomes: A 40-year radical prostatectomy single institution series. J Urol 176:569-574, 2006 (Pubitemid 43927880)
47. Carver BS, Bianco FJ Jr, Scardino PT, et al: Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 176:564-568, 2006 (Pubitemid 43927886)
48. Ward JF, Blute ML, Slezak J, et al: The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170:1872-1876, 2003 (Pubitemid 37254948)
49. Tomlins SA, Laxman B, Varambally S, et al: Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10:177-188, 2008 (Pubitemid 351240884)
50. Klezovitch O, Risk M, Coleman I, et al: A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A 105:2105-2110, 2008 (Pubitemid 351439472)
51. Shappell SB, Thomas GV, Roberts RL, et al: Prostate pathology of genetically engineered mice: Definitions and classification - The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64:2270-2305, 2004 (Pubitemid 38339483)
52. Zong Y, Xin L, Goldstein AS, et al: ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A 106:12465-12470, 2009
53. Arora R, Koch MO, Eble JN, et al: Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100:2362-2366, 2004 (Pubitemid 38657883)
54. Cheng L, Song SY, Pretlow TG, et al: Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 90:233-237, 1998 (Pubitemid 28114542)
55. Greene DR, Wheeler TM, Egawa S, et al: A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol 146:1069-1076, 1991
56. Qian J, Bostwick DG, Takahashi S, et al: Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 55:5408-5414, 1995
57. Sakr WA, Macoska JA, Benson P, et al: Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res 54:3273-3277, 1994 (Pubitemid 24208941)
58. Tomlins SA, Mehra R, Rhodes DR, et al: Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39:41-51, 2007 (Pubitemid 46026500)
59. Clark J, Attard G, Jhavar S, et al: Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 27:1993-2003, 2008 (Pubitemid 351442741)
60. Barry M, Perner S, Demichelis F, et al: TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: Clinical and biologic implications. Urology 70:630-633, 2007 (Pubitemid 350030260)
61. Mehra R, Han B, Tomlins SA, et al: Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: Molecular evidence for an independent group of diseases. Cancer Res 67:7991-7995, 2007 (Pubitemid 47395131)
62. Hessels D, Smit FP, Verhaegh GW, et al: Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 13:5103-5108, 2007 (Pubitemid 47502077)
63. Laxman B, Tomlins SA, Mehra R, et al: Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8:885-888, 2006
64. Laxman B, Morris DS, Yu J, et al: A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 68:645-649, 2008 (Pubitemid 351206738)
65. Barrie SE, Potter GA, Goddard PM, et al: Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 50:267-273, 1994 (Pubitemid 24309119)
66. Attard G, Reid AH, Yap TA, et al: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563-4571, 2008
67. Attard G, Swennenhuis JF, Olmos D, et al: Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69:2912-2918, 2009
68. Wilhelm SM, Adnane L, Newell P, et al: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129-3140, 2008
69. Koivunen JP, Mermel C, Zejnullahu K, et al: EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14:4275-4283, 2008
70. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007 (Pubitemid 47206930)
71. Ateeq B, Tomlins SA, Laxman B, et al: Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 3:72ra17, 2011
72. Berger MF, Lawrence MS, Demichelis F, et al: The genomic complexity of primary human prostate cancer. Nature 470:214-220, 2011
73. Mani RS, Chinnaiyan AM: Triggers for genomic rearrangements: Insights into genomic, cellular and environmental influences. Nat Rev Genet 11:819-829, 2010
74. Ju BG, Lunyak VV, Perissi V, et al: A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science 312:1798-1802, 2006 (Pubitemid 43962898)
75. Haffner MC, Aryee MJ, Toubaji A, et al: Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 42:668-675, 2010
76. Bastus NC, Boyd LK, Mao X, et al: Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res 70:9544-9548, 2010
77. Lin C, Yang L, Tanasa B, et al: Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139:1069-1083, 2009
78. Mani RS, Tomlins SA, Callahan K, et al: Induced chromosomal proximity and gene fusions in prostate cancer. Science 326:1230, 2009